ライフサイエンスコーパス: daily dose

1 uration of use, cumulative dose, and average daily dose.

2 uration of use, cumulative dose, and average daily dose.

3 uration of use, cumulative dose, and average daily dose.

4 HR, 0.61 [95% CI, 0.37-0.98]) of the optimal daily dose.

5 ic side effects as oral prednisone at a 5-mg daily dose.

6 ring range, 0 to -2) or reaching the maximum daily dose.

7 contributing a majority of children's total daily dose.

8 duration, language, and levodopa equivalent daily dose.

9 res in adults who had received a 600 mg once-daily dose.

10 er, and oral naltrexone was given in a 50-mg daily dose.

11 linearly with increasing cumulative dose and daily dose.

12 patients received the same body weight-based daily dose.

13 ral solithromycin or moxifloxacin for 7 once-daily doses.

14 ence of certain structural alerts and higher daily doses.

15 0, or 60mg/kg/day or placebo, divided into 2 daily doses.

16 tively poor BBOX inhibitor and requires high daily doses.

17 d by efficacy, safety concerns, and multiple daily dosing.

18 2-1-1 regimen was a desirable alternative to daily dosing.

19 tic (PK) profile that was predictive of once-daily dosing.

20 ieves stable plasma concentrations with once-daily dosing.

21 MSM was achieved by approximately 1 week of daily dosing.

22 uration of action in vivo, suitable for once-daily dosing.

23 n in asymptomatic carriers during 8 weeks of daily dosing.

24 less with once-daily dosing than with twice-daily dosing.

25 ination half-life (16-17 hours) support once-daily dosing.

26 ibited a plasma half-life supportive of once-daily dosing.

27 (in grams and daily observed doses [defined daily doses]).

28 , 0.57 (95% CI, 0.31 to 1.03) with the 25-mg daily dose, 0.13 (95% CI, 0.04 to 0.38) with the 75-mg d

29 e interval [CI], 0.65 to 1.87) with the 5-mg daily dose, 0.57 (95% CI, 0.31 to 1.03) with the 25-mg d

30 4 [1.33-2.82]), a higher levodopa equivalent daily dose (1.63 [1.09-2.43]), and more frequent exposur

31 use decreased from 120.90 to 110.50 defined daily dose/100 patient-days following introduction of an

32 (adjusted intervention effect -12.12 defined daily dose/100 patient-days; 95% CI, -16.75 to -7.49; p

33 (adjusted intervention effect -3.16 defined daily dose/100 patient-days; 95% CI, -8.33 to 0.04; p =

34 al use decreased from 30.53 to 27.37 defined daily doses/100 patient-days (adjusted intervention effe

35 timicrobial consumption (measured by defined daily doses/100 patient-days) and costs (Canadian dollar

36 ssigned to the celecoxib group (mean [+/-SD] daily dose, 209+/-37 mg), the naproxen group (852+/-103

37 ve 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo.

38 n were randomly assigned to receive a single daily dose (5 mg for 6 weeks, 10 mg for 18 weeks) of don

39 A 6-day regimen of nabiximols (maximum daily dose, 86.4 mg of Delta9-tetrahydrocannabinol and 8

40 he number (and percentage) of patients given daily dosing according to real-weight and ideal-weight g

41 However, daily dosing activated atrophic pathways, including F-bo

42 Chronic steroid use usually involves once-daily dosing, although weekly dosing in children has bee

43 tes increased significantly with the average daily dose among youths with more than 150 days of SSRI

44 for empagliflozin at both the 10- and 25-mg daily doses; analyses comparing empagliflozin versus the

45 The risk of toxicity is dependent on daily dose and duration of use.

46 In view of its once-daily dose and favourable safety profile, WTX101 could i

47 However, daily dosing and split dosing might increase serum hepci

48 Ten women were assigned to receive once-daily dosing and ten were assigned to receive twice-dail

49 , 0.13 (95% CI, 0.04 to 0.38) with the 75-mg daily dose, and 0.32 (95% CI, 0.17 to 0.59) with the 400

50 chemical structure, molecular weight, total daily dose, and complexity of synthesis.

51 BD medication use, total levodopa equivalent daily dose, and dopamine agonist (DA) and antidepressant

52 confidence interval [CI], 69%-100%) after 5 daily doses, and remained >90% for 7 days after stopping

53 ment of chronic non-cancer pain with a total daily dose averaging at least 30 mg (morphine equivalent

54 Daily dosing based on real and ideal weight was calculat

55 Daily dosing based on the older 6.5-mg/kg ideal weight t

56 prescription opioids were prescribed a mean daily dose below 90 mg MED before diagnosis.

57 0 copies/mL were randomized (1:1:1) to twice-daily dose-blinded maribavir 400, 800, or 1200 mg for up

58 ties could lead to an underestimation of the daily dose by a factor of 0.08-1.78.

59 ransgenic mice to greater than 90% with once-daily dosing by inhalation.

60 sers, defined as having a cumulative defined daily dose (cDDD) >/=28, were selected and served as the

61 The cumulative defined daily dose (cDDD), which indicates the exposed duration

62 in use was measured using cumulative defined daily dose (cDDD).

63 escriptions as 30 or more cumulative defined daily doses (cDDDs).

64 s defined as more than 30 cumulative defined daily doses (cDDDs); PPI nonuse was defined as 30 cDDDs

65 no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 +/- 1.3 mg/d), Ctrou

66 MRA after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may allev

67 Data on mean cumulative defined daily doses (DDDs) of MRP inhibitors (NSAIDs, PDE5-i, sa

68 easured as World Health Organization defined daily doses (DDDs) per 1000 patient-days.

69 otics fell by 47% (mean decrease 224 defined daily doses [DDDs] per 1000 OBDs, 95% CI 154-305, p=0.00

70 However, higher daily dose did not increase the risk of optic neuropathy

71 was superior to placebo, but the 5 mg twice daily dose did not show non-inferiority to etanercept 50

72 elective BTK inhibitor that allows for twice-daily dosing due to its selectivity.

73 P also requires greater understanding of the daily dosing duration that is needed to protect the pers

74 thromboprophylaxis (heparin, enoxaparin once-daily dosing, early ambulation), hospital discharge befo

75 higher- (60/30 mg daily) or lower- (30/15 mg daily) dose edoxaban regimen.

76 At oral daily dose-equivalent of 3 mg/kg, 12 exhibited analgesic

77 ctions, superior resistance profile and once-daily dosing favours abacavir for African children, supp

78 ritoneally at 5 min after TBI, followed by a daily dose for 3-21 d.

79 t treatment with nifurtimox (8-10 mg/kg in 3 daily doses for 12 weeks) from March 2008 to July 2012.

80 erine (60 mg/kg) was given orally in divided daily doses for 16 weeks.

81 nd, when administered individually at single daily doses for 8 days in a mice model of Hp infection,

82 ptic shock may need relatively high colistin daily doses for efficacy against multidrug-resistant and

83 in the past, with lower pill burden and once-daily dosing frequency common.

84 The 10-year average daily dose from individual and multivitamin supplements

85 vailability and prolonged exposures for once-daily dosing, good colonic absorption and a reliable con

86 IV-1 RNA were similar for the 40-120 mg once-daily dose groups regardless of baseline Gag polymorphis

87 ng-term, high-intensity use (average defined daily dose >/=0.3) of agents with high cyclooxygenase-2

88 RO2) and found lipophilicity (logP >/=3) and daily dose >/=100 mg of oral medications to be associate

89 e rechallenge exhibit multiple risk factors: daily dose >50 mg, an increased incidence of ALT elevati

90 s, the associations were stronger for higher daily doses (>1.5 vs <0.75 PPI pills/d; P value interact

91 P = 0.002), especially for users with higher daily doses (HR, 0.54; 95% CI, 0.35-0.83; P = 0.005).

92 mfERG and its relationship to cumulative and daily dose illustrates an important role for objective f

93 The median daily dose in the high-dose group was 9 MIU (interquarti

94 not take at least 16 of 21 prescribed total daily doses in cycle 1 because of toxicities attributabl

95 st and efficacious at lowering IOP with once daily dosing in a normotensive mouse model.

96 bodyweights of at least 30 kg and with twice-daily dosing in children with bodyweights of at least 20

97 therapeutic rivaroxaban exposures with once-daily dosing in children with bodyweights of at least 30

98 y at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients.

99 LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advanced t

100 ned that every additional carbapenem defined daily dose increased the hazard of acquiring carbapenem-

101 taken, decreased as the number of prescribed daily doses increased.

102 collection, sex, and the levodopa equivalent daily dose (LEDD), deriving first-pass candidate protein

103 and -complications, and levodopa equivalent daily dose (LEDD).

104 Based on daily dose, lipophilicity, and RM, a DILI score algorith

105 tive metrics, we analyzed the association of daily dose, logP, and formation of reactive metabolites

106 model) defined the relative contribution of daily dose, logP, and RM and permitted a quantitative as

107 wer dosages (40-80 mg Fe) and avoiding twice-daily dosing maximize fractional absorption.

108 cognitive deficits, these data suggest that daily dosing may be critical to allow for development of

109 It is unclear whether the two once-daily dosing non-vitamin K antagonist oral anticoagulant

110 In this preliminary trial, ozanimod at a daily dose of 1 mg resulted in a slightly higher rate of

111 A daily dose of 1 mg TA-8995 increased HDL cholesterol lev

112 A daily dose of 1.4 g of omega-3 PUFAs or placebo (paraffi

113 L/Zi was administrated for 8 weeks at a daily dose of 100 mg/kg BW.

114 centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction

115 f-care initial metformin monotherapy (stable daily dose of 1000 mg, 1500 mg, or 2000 mg) and placebo

116 combination treatment with metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 mg) and vildagli

117 tipation were randomly assigned to receive a daily dose of 12.5 or 25 mg of naloxegol or placebo.

118 3%) were cured after treatment with a single daily dose of 120 mg/kg BKI-1517.

119 12 weeks of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, an

120 coformulated ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, an

121 eatment with ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, an

122 rmulation of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, an

123 A daily dose of 2 g gluten was selected for the interventi

124 or 6 weeks (0.5 mg/day titrated to a maximum daily dose of 2.5 mg).

125 findings support the use of topiramate at a daily dose of 200 mg to reduce heavy drinking in problem

126 eatment with topiramate (N=67), at a maximal daily dose of 200 mg, or matching placebo (N=71).

127 tients were given oral ODM-201 at a starting daily dose of 200 mg, which was increased to 400 mg, 600

128 ned 261 patients to receive lenvatinib (at a daily dose of 24 mg per day in 28-day cycles) and 131 pa

129 who received ombitasvir-ABT-450/r (at a once-daily dose of 25 mg of ombitasvir, 150 mg of ABT-450, an

130 tial benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.

131 ment was <40%, even with the maximum allowed daily dose of 360mg colistin base activity.

132 ment was <40%, even with the maximum allowed daily dose of 360mg colistin base activity.

133 esponse to biologic DMARDs, baricitinib at a daily dose of 4 mg was associated with clinical improvem

134 Simvastatin at a daily dose of 40 mg did not affect exacerbation rates or

135 mized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerb

136 of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy

137 Ibrutinib at a daily dose of 420 mg was administered orally until disea

138 iletine therapy was 36 months, at an average daily dose of 8 +/- 0.5 mg/kg.

139 lemental infant formula given enterally in a daily dose of 8.2 to 9.2 log10 CFU; the placebo was dilu

140 s seen by day 8 in most patients receiving a daily dose of 80 mg or higher.

141 ds (ie, two capsules a day providing a total daily dose of 800 mg docosahexaenoic acid and 225 mg eic

142 0 patients who received colistin at a median daily dose of 9 million IU (MIU; interquartile range, 5.

143 care home residents in the United Kingdom, a daily dose of a probiotic combination of Lactobacillus r

144 The daily dose of ACEI/ARB was independently associated with

145 The mean (SD) daily dose of amisulpride was 272 (168; range, 50-800) m

146 ch an HIV-negative individual takes a single daily dose of an antiretroviral drug so that, if exposed

147 The benefit of the 5 mg twice daily dose of apixaban (n = 8665) compared with warfarin

148 Similarly, the benefit of 5 mg twice daily dose of apixaban compared with warfarin on major b

149 The 5 mg twice daily dose of apixaban is safe, efficacious, and appropr

150 criteria assigned to receive the 5 mg twice daily dose of apixaban or warfarin, 3966 had 1 dose-redu

151 show consistent benefits with the 5 mg twice daily dose of apixaban vs warfarin compared with patient

152 uction criterion who received the 5 mg twice daily dose of apixaban.

153 In contrast, a modest daily dose of BO elevated serum concentrations of GLA an

154 A moderate daily dose of both forms of long-chain omega-3 EFAs, for

155 ociation and statistical interaction of mean daily dose of corticosteroids and intensive care unit le

156 eceived artesunate, administered orally at a daily dose of either 2 mg per kilogram of body weight pe

157 r either the 25-mg once-daily or 75-mg twice-daily dose of evobrutinib, nor in the annualized relapse

158 en of ADMA, Tg-SwDI mice were treated with a daily dose of exogenous ADMA.

159 model outcome is a distribution of a child's daily dose of feces via each exposure route.

160 We established the optimal daily dose of gluten to be used in a 6-week challenge st

161 required for oocyte maturation, whereas the daily dose of gonadotropin or the total number of metaph

162 Daily dose of inhaled corticosteroids (ICS) inversely co

163 Previous phase 1 studies identified a low daily dose of interleukin-2 (IL-2) that was well tolerat

164 ratios associated with exposure to 1 defined daily dose of metformin over the previous 2-7 years were

165 orts of three to six patients and received a daily dose of ODM-201, 200-1800 mg.

166 Treatment with a 50-mg once-daily dose of opicapone was associated with a significan

167 The median daily dose of oral corticosteroids among the 165 patient

168 d fluid restriction of <1000 ml/24 h, a once-daily dose of oral empagliflozin or placebo for 4 days.

169 showed a significant reduction in the lowest daily dose of oral prednisolone throughout the entire tr

170 f those in the placebo group, had an average daily dose of prednisolone or prednisone of 4.0 mg or le

171 002) was obtained, allowing us to reduce the daily dose of prednisone (15.9 +/- 13.6 mg/day vs 3.1 +/

172 feron-alpha2a and lower, conventional 800 mg daily dose of ribavirin.

173 unting for 86.9% of statin use); the defined daily dose of simvastatin was lower in cases than in con

174 d protocol that involved administering a low daily dose of tacrolimus (TAC) to a cohort of 17 patient

175 tective mucosal tissue exposure by the third daily dose of tenofovir disoproxil fumarate plus emtrici

176 -to-severe plaque psoriasis, the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept

177 by the vasopressor-free days and by the mean daily dose of vasopressor to insure a mean arterial pres

178 ctors independently associated with the mean daily dose of vasopressors.

179 RT, the cumulative dose and the mean daily dose of VGB influenced isopters' area obtained wit

180 ter's area and both cumulative dose and mean daily dose of VGB.

181 50.8 nmol/L) (P < 0.0002)].With the use of a daily dose of vitamin D relevant to public health recomm

182 Ten daily doses of 0.1 to 1mg/kg olcegepant yielded similar

183 r pretreatment with olcegepant (single or 10 daily doses of 0.1-1mg/kg) or rimegepant (single doses o

184 given via intraperitoneal and oral routes at daily doses of 0.6 and 0.9 mg/kg, the prodrug was also e

185 f infected mice after an oral dosage of four daily doses of 1.5 mg/kg.

186 armustine applied once in combination with 2 daily doses of 120 mg/m2 of O6-benzylguanine.

187 in a 1:1:1:1 allocation to selonsertib (oral daily doses of 2, 6, or 18 mg) or placebo.

188 re given single doses (phase 1) and repeated daily doses of 2-8 g oral nicotinamide for 5 days (phase

189 tions of vehicle, 200 or 300 mg/kg ISO, or 2 daily doses of 200 mg/kg ISO for 6 days.

190 At once-daily doses of 3 and 10 mg/kg, GLPG1205 reduced disease

191 , patients received oral brigatinib at total daily doses of 30-300 mg (according to a standard 3 + 3

192 Hepatotoxicity was observed in humans at daily doses of 400 mg but was not replicated in any of t

193 or matching placebo, or once-daily or twice-daily doses of ABI-H0731 800 mg or matching placebo for

194 illing >= 2 prescriptions and >= 180 defined daily doses of antihypertensive drugs (AHTs) within a ye

195 Mean daily doses of benzodiazepines and opioids were lower in

196 ntrations in healthy subjects receiving oral daily doses of CPP-115 or placebo.

197 The MDA comprised 3 monthly rounds of 3 daily doses of DP and, except in Cambodia, a single low

198 treat in silico granulomas with recommended daily doses of each FQ and compare efficacy by multiple

199 le administration, and again on Day 10 after daily doses of either 4 mg (Cohorts 1 and 2), or 1 mg (C

200 ervention group received significantly lower daily doses of everolimus and nonsignificantly lower dos

201 ted this prediction by treating rabbits with daily doses of fluoxetine for 2 wk and found that fluoxe

202 Treatment with eight daily doses of IL-37 resulted in a further 326% increase

203 t using topical carmustine plus 2 subsequent daily doses of intravenous O6-benzylguanine, administere

204 ealth care professional, for 3 months vs 270 daily doses of isoniazid, without supervision by a healt

205 n a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor

206 The effect of different daily doses of nitisinone on circulating and 24 h urinar

207 ducted to determine the effect of lower once daily doses of OC000459 and to define the phenotype of s

208 Daily doses of OCA, ranging from 10 to 50 mg, significan

209 th CPY17 inhibitors, to receive one of three daily doses of ODM-201 (200 mg, 400 mg, and 1400 mg).

210 , and were inadequately controlled on stable daily doses of one or two oral glucose-lowering drugs (f

211 scribers that historically prescribed higher daily doses of opioids (>=50 vs <50 mg oral morphine equ

212 e-expansion cohorts assigned to receive once-daily doses of oral gilteritinib (20 mg, 40 mg, 80 mg, 1

213 Higher daily doses of primaquine have the potential to cause cl

214 lent, but 57% of patients took <75% of their daily doses of proguanil.

215 and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight.

216 Daily doses of vitamin D3 for 3 years at 400 IU (n = 109

217 rmacodynamic modelling exercises, that twice daily dosing of artemisinins increases malaria parasite

218 In a 2-week mouse xenograft model, daily dosing of compound 28 resulted in 33% tumor regres

219 ed with 43 subjects assigned to receive once daily dosing of either placebo (n = 21) or JNJ-42165279

220 cks within strata to receive open-label oral daily dosing of erlotinib (150 mg), cabozantinib (60 mg)

221 No patient had daily dosing of more than 5 mg/kg based on real weight a

222 n this randomized, double-masked trial, once-daily dosing of netarsudil 0.02% was effective, consiste

223 ed, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effecti

224 transiently ameliorate hyperglycemia through daily dosing of one or more antidiabetic drugs.

225 -life of 12-48 h is generally ideal for once daily dosing of oral drugs.

226 bility and acceptability of daily versus non-daily dosing of oral HIV pre-exposure prophylaxis (PrEP)

227 formed under maximal acid suppression (twice daily dosing of proton pump inhibitor therapy) in 8-12 w

228 acilitated by vancomycin preconditioning and daily dosing of SER-287.

229 t disease modifying benefits associated with daily dosing of SMT022357, a second-generation compound

230 After a 2-week run-in period with twice-daily dosing of Systane Balance (Alcon, Fort Worth, TX),

231 s tumor suppression equivalent to a month of daily dosing of talazoparib.

232 eractivity on Days 4 to 7 after the repeated daily dosing of the drug.

233 l ones throughout timepoints either by total daily dose or adjusted (Adj) per body weight.

234 y halving their ICS dose (halving their mean-daily dose or their inhaler dose).

235 2.18, 95% CI 1.01-4.70), and receiving twice-daily dosing (OR 2.81, 95% CI 1.47-5.36) were associated

236 ng (OR, 2.18 [95% CI, 1.01-4.70]), and twice-daily dosing (OR, 2.81 [95% CI, 1.47-5.36]) were associa

237 There was no systemic accumulation following daily doses over ten days.

238 ing (P=0.024) and 93.5% for patients on once-daily dosing (P=0.008).

239 igher serum hepcidin concentration than once-daily dosing (p=0.013).

240 d 84%, compared to 91% for patients on twice-daily dosing (P=0.024) and 93.5% for patients on once-da

241 ps (73% +/- 26% vs 46% +/- 28% of prescribed daily doses; P < .0001), but not between PAD and non-PAD

242 Monthly drug consumption data in defined daily doses per 100 bed-days and incidence densities of

243 ed to a reduction in mean antibiotic defined daily doses per 100 patient-days from 101.38 (95% CI 93.

244 n was assessed with the WHO index of defined daily doses per 100 patient-days, and the primary outcom

245 28, p=0.008) and the community (1.85 defined daily doses per 1000 inhabitant-days, 95% CI 0.23-3.48,

246 ntervention (change in level, -216.8 defined daily doses per 1000 OBDs; 95% confidence interval, -347

247 n both hospitals (mean reduction 193 defined daily doses per 1000 occupied bed-days, 95% CI 45-328, p

248 ce was observed in all 12 volunteers for the daily dosing period.

249 on cost-savings, ease, and convenience of a daily-dosing pill.

250 Yet, the average daily dose prescribed remained below guideline recommend

251 confirmed 93% versus 63% DOT (p < 0.001) of daily doses prescribed.

252 Daily dose profiles capturing 28 days of continuous dosi

253 Daily dosing profiles were consistent with a model of MV

254 of use (Ptrend = .036) and higher prescribed daily dose (Ptrend = .016).

255 Daily doses ranged from 20 mg to 60 mg for citalopram (m

256 ively breastfed infants received <20% of the daily dose recommended by the Institute of Medicine for

257 The daily dose recommended by the US Food and Drug Administr

258 racterize the profiles of single doses and a daily dose regimen of MVC.

259 verse effects or switch to the use of a once-daily dosing regimen due to compliance issues.

260 However, daily dosing regimen has augmented non-adherence.

261 he concentration-dependent activity and once-daily dosing regimen of telavancin.

262 After a daily dosing regimen, a shift to excitatory-inhibitory b

263 short half-life, necessitating a three times daily dosing regimen.

264 gical half-life of 10.5 h, suggesting a once-daily dosing regimen.

265 hly dependent on strict patient adherence to daily dosing regimen.

266 or in patients receiving once-daily vs twice-daily dosing regimens.

267 t of patients started at a 120 mg continuous daily dosing schedule, different from the standard inter

268 ealth-care or lay worker, with any remaining daily doses self-administered.

269 ed for upadacitinib efficacy; the 30-mg once-daily dose showed the greatest clinical benefit.

270 atients continued filling prescriptions with daily doses similar to chronic opioid users ( P = .05),

271 an immunodeficiency virus (HIV) include once-daily dosing, simplification of co-treatment for tubercu

272 Its twice daily dosing, suitability for intravenous, oral, or swit

273 chronic use were more likely to have a high daily dose than controls with chronic use in the first 3

274 option for supervision of daily and multiple daily doses than DOT.

275 time, but adherence decreased less with once-daily dosing than with twice-daily dosing.

276 t attainment rates for FDA- and EMA-approved daily doses to achieve colistin Css,avg of >/=0.5, >/=1,

277 Antiretroviral therapy requires lifelong daily dosing to attain viral suppression, restore immune

278 opioid prescriptions, 5 distinct prescribed daily dose trajectories preceding diagnosis emerged: con

279 Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profil

280 HRs for type-specific CVDs and <5.0-mg daily dose use were: 1.69 (95% CI 1.54-1.85) for atrial

281 The median daily dose was 0.21 (0.20-0.21) million international un

282 The median daily dose was 660 mg (IQR 389.2-800.0) sorafenib versus

283 Each 25-mg increase in morphine equivalent daily dose was associated with an 11.2% increase in the

284 nitial dose of once-daily 350 mug Triac, the daily dose was increased progressively in 350 mug increm

285 remained in CR, and 20% were in PR after the daily dose was reduced by 50%.

286 In 3 patients (27%), daily dosing was 5 mg/kg or less based on real weight an

287 In 4 patients (36%), daily dosing was 5 mg/kg or less based on real weight an

288 In 4 patients (36%), daily dosing was more than 5 mg/kg based on real weight

289 Mean TAC trough level (Cmin), used to adjust daily dose, was not different between the 2 groups in al

290 By defined daily dose, we found a 6.1% (-7.5% - -4.7%) overall decr

291 Median duration of treatment and mean daily dose were 12.5 months (IQR 2.6-35.8) and 577 mg pe

292 of antihypertensive medications and defined daily dose were less in the RDN group than in the sham g

293 Mean daily doses were 4.2 mg (SD 0.6) for cariprazine and 3.8

294 Although the daily doses were ~33% above the upper limit of the FDA-

295 sification of ICS doses based on a "standard daily dose," which is defined as 200-250 mug of fluticas

296 renia were randomly assigned to receive once-daily dosing with 10 mg of ABT-126, 25 mg of ABT-126, or

297 tudy provides preliminary evidence that once-daily dosing with dasotraline, a long-acting, dual monoa

298 e was escalated to 7,000 mg per day in twice-daily dosing with no DLTs; however, plasma lapatinib con

299 tial combination of ibrutinib (560 or 840 mg daily dosing) with high-dose methotrexate (HD-MTX) and r

300 ) a study giving three 60-mg Fe doses (twice-daily dosing) within 24 hours (study 3, n = 13).